

## Supplementary Materials

# Modelling uncertainty in the relative risk of exposure to the SARS-CoV-2 virus by airborne aerosol transmission in well mixed air in Buildings

Benjamin Jones<sup>a,\*</sup>, Patrick Sharpe<sup>a</sup>, Christopher Iddon<sup>b</sup>, E Abigail Hathway<sup>c</sup>, Catherine J Noakes<sup>d</sup>, Shaun Fitzgerald<sup>e</sup>

<sup>a</sup>*Department of Architecture and Built Environment, University of Nottingham, Nottingham, UK*

<sup>b</sup>*Chartered Institution of Building Services Engineers Natural Ventilation Special Interest Group, 222 Balham High Road, London, UK*

<sup>c</sup>*Department of Civil and Structural Engineering, University of Sheffield, Sheffield, UK*

<sup>d</sup>*School of Civil Engineering, University of Leeds, Leeds, UK*

<sup>e</sup>*Department of Engineering, Cambridge University, Cambridge, UK*

---

### Abstract

This document provides supplementary work to paper given in the title: B. Jones, P. Sharpe, C. Iddon, E.A. Hathaway, C. Noakes, S. Fitzgerald. Modelling uncertainty in the relative risk of exposure to the SARS-CoV-2 virus by airborne aerosol transmission in well mixed air in Buildings. *Energy & Buildings*. 2021.

---

---

\*Corresponding author

*Email address:* benjamin.jones@nottingham.ac.uk (Benjamin Jones)

## 1 **1. Viral load and viability**

2       The viability of the airborne virions encapsulated in aerosols of respira-  
3 tory fluid decreases over time through various biological processes. Respi-  
4 ratory fluid is a complex composition of proteins, salts and surfactants and  
5 the evaporation of the droplet results in an increase in concentration of these  
6 components, which may have an impact on the viability of any encapsulated  
7 virions [1]. Biological decay will consider the half-life of the infectivity of  
8 the virion containing aerosols which has been measured in the laboratory  
9 with median estimates of approximately 1.1 to 1.2 hours and 95% credible  
10 intervals of 0.64 to 2.64 for SARS-CoV-2 [2].

## 11 **2. Aerosol size, breathing rate and viral load of respiratory fluid**

12       Larger droplets produced by expiratory activities, associated with close-  
13 proximity direct virus transfer or fomite transmission, or which can become  
14 resuspended in air at a later point in time, are not considered in this aerosol  
15 airborne transmission model.

16       The model considers small droplets and droplet nuclei  $< 5 \mu\text{m}$  that can  
17 become entrained in air flows and remain airborne for several hours.

18       Several studies have measured the range of aerosol sizes emitted during  
19 various expiratory activities, although primarily coughs and sneezes, using  
20 a range of methodologies [3, 4, 5, 6] and compared by Vuorinen *et al.* [7].  
21 There is a wide variation between individuals taking part in the studies in  
22 terms of volumes of aerosols generated through speaking; suggesting a high  
23 degree of variability amongst individuals and could in part be related to

24 the concept of superspreaders, contagious individuals who appear to infect a  
25 greater number of secondary individuals, but it is not confirmed.

26 Recently, the growing availability of higher temporal and spatial visu-  
27 alization methods using high-speed cameras [8], particle image velocimetry  
28 [5] and, above all, increasingly accurate particle counters [9] has allowed the  
29 detailed characterization and quantification of droplets expelled during vari-  
30 ous forms of human respiratory exhalation flows (e.g. breathing, whispering,  
31 speaking, coughing). This knowledge can be used to estimate the viral load  
32 emitted by someone shedding RNA copies into an indoor setting.

33 Many of the studies on droplet and aerosol expiration have focused on  
34 coughs and sneezes. However, as the purpose of this study is to consider  
35 asymptomatic and presymptomatic infective individuals, the aerosol gen-  
36 eration rate of breathing and talking is of more interest. As most of the  
37 aerosols generated by breathing are sub  $5\ \mu\text{m}$ , the model uses data produced  
38 by Morawska *et al.* which not only measured the volume of sub  $5\ \mu\text{m}$  aerosols  
39 recorded during breathing but also compared with other expiratory activities  
40 that may be conducted by an asymptomatic or pre-symptomatic individual;  
41 namely talking and vocalisation (singing an “*aaah*”) which was observed to  
42 produce more than 3 and 11 times the number of droplets as produced by  
43 mouth breathing, respectively [9]. A  $5\ \mu\text{m}$  droplet of pure water evaporates  
44 in 0.8 seconds, thus it is assumed that the droplets achieve their equilibrium  
45 size before reaching the measurement probe. The aerosols expelled at the  
46 mouth could be up to 5 times larger than the measured aerosol, representa-  
47 tive of aerosols with an original diameter of up to  $27.5\ \mu\text{m}$  and an original  
48 volume 125 times greater than the measured aerosol [9, 10].

49 The number of aerosols are recorded per  $\text{cm}^3$  of expired air. To establish  
 50 a rate of RNA copies emitted by an infector Adams *et al.* will be used as a  
 51 source of average inhalation rates under various activities [11].

52 The viral load of respiratory fluid is an important risk factor. A small  
 53 study recently found the average RNA concentration in sputum of COVID-  
 54 19 patients to be  $7.00 \times 10^6$  copies per ml, but with a maximum of  $2.35 \times$   
 55  $10^9$  copies per ml. During the first week of virus collection 83% of sputum  
 56 samples were shown to contain viable virus in plaque assays [12]. Miller *et al.*  
 57 suggest that the RNA concentration could be as high as  $1.00 \times 10^{11}$  copies per ml  
 58 calculated from RNA copies measured in the air a COVID-19 patient in Sin-  
 59 gapore [13, 14]. This is a very wide range, of several orders of magnitude.

60 Using Morawska *et al.* data a total volume of respiratory fluid emitted  
 61 per cubic metre of exhaled air is calculated. The volume is then used to  
 62 generate a weighted average droplet diameter which is used in the model,  
 63 along with the total number of droplets emitted.

Table 1: Number of aerosols in each bin per  $\text{cm}^3$  of air in upper respiratory tract.

diameter ( $\mu\text{m}$ )	0.800	1.800	3.500	5.500	TOTAL
voiced counting	0.236	0.068	0.007	0.011	0.322
whisper counting	0.110	0.014	0.004	0.002	0.130
vocalisation	0.751	0.139	0.139	0.059	1.088
whisper	0.636	0.037	0.000	0.000	0.673
mouth breathing	0.084	0.009	0.003	0.002	0.098
cough	0.567	0.093	0.012	0.006	0.678

Table 2: Volume ( $\text{m}^3$ ) of respiratory fluid aerosol in each bin per  $\text{m}^3$  of exhaled air  $\times 10^{-14}$ .

Diameter ( $\mu\text{m}$ )	0.8	1.8	3.5	5.5	TOTAL
voiced counting	6.33	20.76	15.71	95.83	138.63
whisper counting	2.95	4.28	8.98	17.42	33.63
vocalisation	20.13	42.45	312.05	513.97	888.59
whisper	17.05	11.30	0.00	0.00	28.35
mouth breathing	2.25	2.75	6.73	17.42	29.16
cough	15.20	28.40	26.94	52.27	122.81

Table 3: Weighted average diameter of aerosols for each respiratory activity ( $\mu\text{m}$ ).

voiced counting	2.02
whisper counting	1.70
vocalisation	2.50
whisper	0.93
mouth breathing	1.78
cough	1.51

Table 4: Viral genomes exhaled assuming a viral load of  $3 \times 10^9$  RNA copies per ml respiratory fluid of infector and a breathing rate of  $0.558 \text{ m}^3$  per hour.

Activity	per $\text{m}^3$ exhaled air	per hour	per minute	ratio to breathing
voiced counting	519866	290085	4835	4.75
whisper counting	126099	70363	1173	1.15
vocalisation	3332230	1859385	30990	30.48
whisper	106307	59319	989	0.97
mouth breathing	109341	61012	1017	1.00
cough	460524	256972	4283	4.21

64 Using Tables 1—4, the generated weighted average diameter of droplets  
65 for mouth breathing is  $1.78 \times 10^{-6}$  m. The number of droplets per  $\text{m}^3$  of  
66 exhaled breath is 98000 (0.098 per  $\text{cm}^3$ ) for breathing.

67 The volume of fluid in respiratory *aerosols* is  $98000 \times$  the volume of  
68 weighted *aerosols*. The sedentary breathing rate for a male [11] is  $0.558 \text{ m}^3$   
69 per hour.

70 Assuming an RNA load of  $3 \times 10^9$  copies per ml (at the high range from  
71 Wölfel *et al.* [12]), we multiply this by  $5^3 = 125$  on the basis that the mea-  
72 sured diameter of the droplets by Morawska *et al.* could be 5 times smaller  
73 than the original droplets (i.e. they evaporate on their journey between  
74 the mouth and the counting instrument) and therefore the original number  
75 of RNA copies in the droplet will be 125 times greater. Stadnytskyi *et al.*  
76 [10, 9] give a value of  $3.75 \times 10^{17}$  RNA copies per  $\text{m}^3$  of respiratory fluid.

77  $109341 \text{ RNA per m}^3 \text{ exhaled air} \times 0.558 \text{ m}^3 \text{ per hour} = 61012 \text{ RNA copies}$   
78  $\text{per hour (1017 RNA copies emitted per minute)}$ .

79 This is comparable with Ma *et al.* who estimate between 1000–100,000 RNA  
80 copies per minute when breathing (although this is in full range of droplets,  
81 so assume 100,000 per minute, 1% of total expired volume in aerosols = 1000  
82 per minute) [15].

83 In contrast Miller *et al.* assumes 1000-10,000 infectious virions per hour  
84 (assume 1 virion per 1000 RNA copies) =  $10^6$ – $10^7$  RNA copies per hour  
85 (16,667—166,667 RNA copies per minute), although this RNA load is repre-  
86 sentative of a superspreader [13].

### 87 **3. RNA concentration in respiratory fluid**

88 Breathing and respiratory fluid RNA measurements from COVID-19 pa-  
89 tients [12, 15] are used to estimate  $C_{RNA}$ . The literature shows a high vari-  
90 ability in the concentration of SARS-CoV-2RNA in respiratory secretions  
91 ranging from  $7.00 \times 10^6$  to  $1.00 \times 10^{11}$  RNA copies per ml [10, 12, 13]. In the  
92 paper we assume an RNA concentration of  $3 \times 10^9$  RNA copies per ml, which  
93 is equivalent to emitting 16.5 RNA copies per second by breathing. This value  
94 is comparable with the lower values of 17 to 1667 RNA copies per second given  
95 by Ma *et al.* [15] and the 4.6 RNA copies per second estimated by Miller *et al.*  
96 [13] and Chia *et al.* [14] from airborne RNA copies sampled from infected  
97 patients in Singapore. We assume that the concentration of RNA copies per  
98 ml in respiratory aerosols is 125 times greater to account for evaporation,  
99 which reduces the diameter of the exhaled droplets up to five-fold when es-  
100 timating the total number of RNA copies modelled in aerosols of  $5.5 \mu\text{m}$  and  
101 smaller [10]. The size distribution data was measured by Morawska *et al.*  
102 to be sufficiently far away from the respiring source to have allowed time  
103 for evaporation, thus the measured  $5.5 \mu\text{m}$  diameter aerosols are assumed to  
104 have been  $27.5 \mu\text{m}$  at source.

### 105 **4. Why ventilation flow should be measure in volume per time**

106 The figures in this section highlight why using common ventilation termi-  
107 nology of Air Changes per Hour ( $\text{h}^{-1}$ ) or flow per person per unit time (e.g  
108  $1 \text{ l s}^{-1}$  per person) are not suitable when providing guidance on ventilation  
109 rates to minimise the Relative Exposure Index of a space.

110 *4.1. Air changes per hour*

111 If we consider a case with the same attributes as the Reference Scenario  
112 classroom, but with  $1 \text{ h}^{-1}$  and a variable volume, Figure 1 shows that  $1 \text{ h}^{-1}$   
113 is insufficient in small volume spaces, and over sufficient in very large spaces  
114 – because the flow rate per unit time is what drives the ventilation dilution  
115 of airborne pollutant.




Figure 1: Number of RNA inhaled in spaces, equivalent to the Reference Case, of varying volume with ventilation flow rate of  $1 \text{ h}^{-1}$ .

116 *4.2. Ventilation flow per person per unit time*

117 If we consider a case with the same attributes as the Reference Case class-  
118 room, but with varying occupancy and a ventilation flow of  $10 \text{ l s}^{-1}$  per per-  
119 son Figure 2 shows that  $10 \text{ l s}^{-1}$  per person is insufficient to reduce the REI  
120 when occupancy is low because the total flow rate per unit time is what  
121 drives the ventilation dilution of airborne pollutant.






Figure 2: Number of RNA inhaled in Reference Spaces with varying occupancy and a ventilation flow rate of  $10 \text{ l s}^{-1}$  per person.

122 In the reference case (discussed in the paper), the flow rate required for  
 123 an  $REI = 1.00$  a flow rate of  $160 \text{ l s}^{-1}$  is required.

#### 124 4.3. Respiratory activities effect on REI

125 Considering the reference case scenario we consider the index case infector  
 126 either breathing, talking or vocalisation for the duration of the occupancy  
 127 period. It is clear that the respiratory activity

128 Note for vocalisation we have not modelled the increase in breathing rate  
 129 that would be likely (up to 165% increase suggested by Bernardi *et al.* [16])  
 130 so the inhaled RNA copies would be even greater.




Figure 3: Number of RNA inhaled in Reference Space ventilated at 5l/s/person with the infector undertaking different respiratory activities for the duration of the occupied time.

131 *4.4. Viral load*

132 The viral load in the respiratory fluid of an infector can vary over several  
 133 orders of magnitude [13, 12]. Figure 4 shows how the inhaled RNA copies is  
 134 dependent upon the RNA copies load in the respiratory fluid of the infector.  
 135 The reference case assumes a relatively high load of  $3 \times 10^9$  RNA copies per  
 136 ml, however, although the load does not affect the REI, it does affect the  
 137 inhaled dose of RNA copies and therefore the potential for inhaling infective  
 138 virions. If the infector RNA load is in the order of  $10^6$  then in the reference  
 139 case the inhaled RNA copies is  $< 1.00$  and far field airborne transmission  
 140 is therefore unlikely. As the RNA load in the respiratory fluid increases, so  
 141 does the probability of airborne transmission. It is likely that in 1000 RNA  
 142 copies there may only be 1 viable virion so the probability of infection is  
 143 exacerbated by the REI [17]. Even with very low REI values it is likely that

144 a superspreader will result in sufficient airborne RNA to be inhaled to lead  
145 to infection, but such persons are rare, and therefore using the REI to drive  
146 down the risk of an indoor space and activity will result in reducing secondary  
147 transmissions, keeping the population  $R(t)$  value as low as possible.




Figure 4: Number of RNA inhaled in Reference Space with varying viral load of infector.






Figure 6: Visualisation of the effect of Occupation Length, Ventilation, Room Volume and Respiratory Activity on REI. Using the breathing rate of Male Sitting, this image demonstrates how the RRI changes with respect to increasing the occupation time and with reduced ventilation and smaller room volumes. Values are rounded to nearest whole number. Note that RRI reference case is a junior classroom with child breathing rates, hence the higher RRI for adult male sitting.

## 148 5. Statistical framework

149 The sampling method follows that described by [18, 19, 20]. The model  
150 requires input variates that are either specified deterministically or described  
151 by continuous probability distributions to predict  $\sum n$ .

152 Deterministic inputs used by all simulations are given in Table 2 in the  
153 paper. Five probabilistic inputs apply to all scenarios and their distribu-  
154 tions and their governing statistics are given in Table 2 in the main paper.  
155 Probabilistic inputs that vary by space type are given in Table 3 in the main  
156 paper for each simulated scenario. The values of each probabilistic input  
157 using Latin Hypercube Sampling (LHS) to improve the stratification of sam-  
158 ples over the probability space [21] and reduces the number of simulations  
159 required to reach convergence. They generate a value between 0 and 1 for  
160 each input, which are then applied to their inverse cumulative distribution  
161 functions (CDF) to generate an input.

162 Predictions of  $\sum n$  are obtained for a set of 1000 samples and a mean  $\sum n$   
163 is obtained for each set. After 10 sets ( $10^5$  samples), the means are tested  
164 for normality using a one-sample Kolmogorov-Smirnov test, and sampling is  
165 stopped when this test is found to be true ( $p$ -value  $< .01$ ). Only 10 sets were  
166 required to achieve normality in the distribution for all data sets described  
167 herein.

168 For one-off deterministic calculations (see Section 3.1 in the main paper)  
169 mean values are used for normally and log-normally distributed variables,  
170 and central values are used for uniformly distributed variables.

171 A sensitivity analysis is used to test the dependence of  $\sum n$  on the model

172 inputs. Here, the method and code<sup>1</sup> [19] of Jones *et al.* is applied and  
173 a full description is found in the reference. The method tests for linear  
174 (Kendall’s  $\tau$ , Pearson’s  $r$ , linear regression), monotonic (Spearman’s  $\rho$ , and  
175 rank-transformed standardised variables), and non-monotonic (Kolmogorov–  
176 Smirnov and Kruskal–Wallis quantile tests) relationships between inputs and  
177 outputs. All inputs are ranked by the magnitude of the regression coefficient.  
178 Reported  $p$ -values are used to determine variate statistical significant at a  
179 5% level.

180 A fundamental requirement of a sensitivity analysis is that all tested  
181 inputs are independent of one another, and so co-dependent variables should  
182 combined. There are no co-dependenent variable in this analysis, but there  
183 could be in the future. For example,  $\gamma_m$  and  $G$  are both a function of droplet  
184 diameter but the paucity of data for  $\gamma_m$  means that it is not considered  
185 independently of  $\gamma$ .

186 To quantify the magnitude of the differences between predicted  $\sum n$  for  
187 the reference space and other spaces, an effect size is used following Ferguson  
188 [22] and using Cohen’s  $d$ . Thresholds are used to label the effects where  
189  $d < 0.2$  corresponds to a *negligible* effect size,  $0.2 \leq d < 0.5$  to a *small* effect  
190 size,  $0.5 \leq d < 0.8$  to *medium* effect size,  $0.8 \leq d < 1.3$  to a *large* effect size, and  
191  $d \geq 1.3$  corresponds to a *very large* effect size.

---

<sup>1</sup>The code was used under a creative commons license and obtained from DOI:  
10.13140/RG.2.2.21670.88644

192 **References**

- 193 [1] E. P. Vejerano, L. C. Marr, Physico-chemical characteristics of evapo-  
194 rating respiratory fluid droplets, *Journal of the Royal Society Interface*  
195 15 (139) (2018) 1–10. doi:10.1098/rsif.2017.0939.
- 196 [2] N. van Doremalen, T. Bushmaker, D. H. Morris, M. G. Holbrook,  
197 A. Gamble, B. N. Williamson, A. Tamin, J. L. Harcourt, N. J. Thorn-  
198 burg, S. I. Gerber, et al., Aerosol and surface stability of sars-cov-2 as  
199 compared with sars-cov-1, *New England Journal of Medicine* 382 (16)  
200 (2020) 1564–1567. doi:10.1056/NEJMc2004973.
- 201 [3] J. P. Duguid, The Size and the Duration of Air-Carriage of Respiratory  
202 Droplets and Droplet-Nuclei, *The Journal of Hygiene* 44 (6) (1946) 471–  
203 9. doi:10.1017/s0022172400019288.
- 204 [4] M. Nicas, W. W. Nazaroff, A. Hubbard, Toward understanding the risk  
205 of secondary airborne infection: Emission of respirable pathogens, *Jour-  
206 nal of Occupational and Environmental Hygiene* 2 (3) (2005) 143–154.  
207 doi:10.1080/15459620590918466.
- 208 [5] C. Y. H. Chao, M. P. Wan, L. Morawska, G. R. Johnson, Z. Ristovski,  
209 M. Hargreaves, K. Mengersen, S. Corbett, Y. Li, X. Xie, et al., Char-  
210 acterization of expiration air jets and droplet size distributions imme-  
211 diately at the mouth opening, *Journal of Aerosol Science* 40 (2) (2009)  
212 122–133. doi:10.1016/j.jaerosci.2008.10.003.
- 213 [6] X. Xie, Y. Li, H. Sun, L. Liu, Exhaled droplets due to talking and



- 214 coughing, *Journal of the Royal Society Interface* 6 (SUPPL. 6) (2009).  
215 doi:10.1098/rsif.2009.0388.focus.
- 216 [7] V. Vuorinen, M. Aarnio, M. Alava, V. Alopaeus, N. Atanasova, M. Au-  
217 vinen, N. Balasubramanian, H. Bordbar, P. Erästö, R. Grande, N. Hay-  
218 ward, A. Hellsten, S. Hostikka, J. Hokkanen, O. Kaario, A. Karvinen,  
219 I. Kivistö, M. Korhonen, R. Kosonen, J. Kuusela, S. Lestinen, E. Laurila,  
220 H. Nieminen, P. Peltonen, J. Pokki, A. Puisto, P. Råback, H. Salmen-  
221 joki, T. Sironen, M. Österberg, Modelling aerosol transport and virus  
222 exposure with numerical simulations in relation to SARS-CoV-2 trans-  
223 mission by inhalation indoors, *Safety Science* 130 (May) (2020) 104866.  
224 arXiv:2005.12612, doi:10.1016/j.ssci.2020.104866.  
225 URL <http://arxiv.org/abs/2005.12612>
- 226 [8] J. W. Tang, C. J. Noakes, P. V. Nielsen, I. Eames, A. Nicolle,  
227 Y. Li, G. S. Settles, Observing and quantifying airflows in the infec-  
228 tion control of aerosol- and airborne-transmitted diseases: An overview  
229 of approaches, *Journal of Hospital Infection* 77 (3) (2011) 213–222.  
230 doi:10.1016/j.jhin.2010.09.037.
- 231 [9] L. Morawska, G. R. Johnson, Z. D. Ristovski, M. Hargreaves,  
232 K. Mengersen, S. Corbett, C. Y. Chao, Y. Li, D. Katoshevski, Size  
233 distribution and sites of origin of droplets expelled from the human res-  
234 piratory tract during expiratory activities, *Journal of Aerosol Science*  
235 40 (3) (2009) 256–269. doi:10.1016/j.jaerosci.2008.11.002.
- 236 [10] V. Stadnytskyi, C. E. Bax, A. Bax, P. Anfinrud, The airborne lifetime  
237 of small speech droplets and their potential importance in SARS-CoV-2

- 238 transmission., Proceedings of the National Academy of Sciences of the  
239 United States of America (2020) 3–5doi:10.1073/pnas.2006874117.  
240 URL <http://www.ncbi.nlm.nih.gov/pubmed/32404416>
- 241 [11] A. WC, Measurement of breathing rate and volume in routinely per-  
242 formed daily activities, Final report, contract no. a033-205., California  
243 Air Resources Board, Sacramento (1996).
- 244 [12] R. Wölfel, V. M. Corman, W. Guggemos, M. Seilmaier, S. Zange, M. A.  
245 Müller, D. Niemeyer, T. C. Jones, P. Vollmar, C. Rothe, M. Hoelscher,  
246 T. Bleicker, S. Brünink, J. Schneider, R. Ehmann, K. Zwirgmaier,  
247 C. Drosten, C. Wendtner, Virological assessment of hospitalized patients  
248 with COVID-2019, Nature 581 (March) (2020). doi:10.1038/s41586-020-  
249 2196-x.  
250 URL <http://dx.doi.org/10.1038/s41586-020-2196-x>
- 251 [13] S. L. Miller, W. W. Nazaroff, J. L. Jimenez, A. Boerstra, S. J. Dancer,  
252 J. Kurnitski, L. C. Marr, L. Morawska, C. Noakes, Transmission of  
253 SARS-CoV-2 by inhalation of respiratory aerosol in the Skagit Valley  
254 Chorale superspreading event, MedRxiv preprint preprint (June) (2020)  
255 1–17. doi:<https://doi.org/10.1101/2020.06.15.20132027>.
- 256 [14] P. Y. Chia, K. K. Coleman, Y. K. Tan, S. Wei, X. Ong, M. Gum,  
257 S. K. Lau, X. F. Lim, A. S. Lim, S. Sutjipto, P. H. Lee, T. T. Son,  
258 B. E. Young, D. K. Milton, G. C. Gray, S. Schuster, T. Barkham, P. P.  
259 De, S. Vasoo, M. Chan, B. Sze, P. Ang, Detection of air and surface  
260 contamination by SARS-CoV-2 in hospital rooms of infected patients, ?  
261 (2020). doi:10.1038/s41467-020-16670-2.

- 262 [15] J. Ma, X. Qi, H. Chen, X. Li, Z. Zhang, H. Wang, L. Sun,  
263 L. Zhang, J. Guo, L. Morawska, S. A. Grinshpun, P. Biswas,  
264 R. C. Flagan, M. Yao, Covid-19 patients in earlier stages ex-  
265haled millions of sars-cov-2 per hour, *Clinical Infectious Diseases-*  
266 *Ciaa1283* (08 2020). arXiv:[https://academic.oup.com/cid/advance-](https://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciaa1283/33693557/ciaa1283.pdf)  
267 [article-pdf/doi/10.1093/cid/ciaa1283/33693557/ciaa1283.pdf](https://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciaa1283/33693557/ciaa1283.pdf),  
268 doi:10.1093/cid/ciaa1283.  
269 URL <https://doi.org/10.1093/cid/ciaa1283>
- 270 [16] N. F. Bernardi, S. Snow, I. Peretz, H. D. Orozco Perez, N. Sabet-  
271 Kassouf, A. Lehmann, Cardiorespiratory optimization during im-  
272 proved singing and toning, *Scientific Reports* 7 (1) (2017) 1–8.  
273 doi:10.1038/s41598-017-07171-2.  
274 URL <http://dx.doi.org/10.1038/s41598-017-07171-2>
- 275 [17] J. Yan, M. Grantham, J. Pantelic, P. J. B. De Mesquita, B. Albert,  
276 F. Liu, S. Ehrman, D. K. Milton, Infectious virus in exhaled breath of  
277 symptomatic seasonal influenza cases from a college community, *Pro-*  
278 *ceedings of the National Academy of Sciences of the United States of*  
279 *America* 115 (5) (2018) 1081–1086. doi:10.1073/pnas.1716561115.
- 280 [18] P. Das, C. Shrubsole, B. Jones, I. Hamilton, Z. Chalabi, M. Davies,  
281 A. Mavrogianni, J. Taylor, Using probabilistic sampling-based sensitiv-  
282 ity analyses for indoor air quality modelling, *Building and Environment*  
283 78 (2014) 171–182.
- 284 [19] B. Jones, P. Das, Z. Chalabi, M. Davies, I. Hamilton, R. Lowe, A. Mavro-  
285 gianni, D. Robinson, J. Taylor, Assessing uncertainty in housing stock

- 286 infiltration rates and associated heat loss: English and UK case studies,  
287 Building and Environment 92 (2015) 644–656.
- 288 [20] C. O’Leary, B. Jones, S. Dimitroulopoulou, I. Hall, Setting  
289 the standard: The acceptability of kitchen ventilation for the  
290 english housing stock, Building and Environment (2019) In-  
291 doi:<https://doi.org/10.1016/j.buildenv.2019.106417>.  
292 URL [http://www.sciencedirect.com/science/article/pii/  
293 S0360132319306274](http://www.sciencedirect.com/science/article/pii/S0360132319306274)
- 294 [21] J. C. Helton, F. J. Davis, Latin hypercube sampling and the propagation  
295 of uncertainty in analyses of complex systems, Reliability Engineering  
296 & System Safety 81 (1) (2003) 23–69.
- 297 [22] C. J. Ferguson, An effect size primer: A guide for clinicians and re-  
298 searchers, Professional Psychology: Research and Practice 40 (5) (2009)  
299 532.